diaTribe Change Letter Documents
At diaTribe Change, our mission is to improve the lives of people with diabetes and prediabetes through informed policy advocacy and education. Our work involves engaging in regulatory and legislative actions to influence policies that significantly impact the diabetes community. Recently, our team has focused on crafting regulatory comment letters to advocate for changes that can enhance diabetes care and prevention.
We are excited to share our recent advocacy efforts with you. Below, you will find links to the regulatory comment letters we have written, reflecting our commitment to making a meaningful impact:
diaTribe Foundation Comments Re: Insulin Icodec FDA Advisory Committee — May 2024
diaTribe Foundation Comments Re: FDA Home as a Health Care Hub Initiative —July 2024
diaTribe Foundation Comments Re: CDRH Health Equity Discussion Draft — October 2024
diaTribe Foundation Comments Re: Sotagliflozin FDA Advisory Committee — October 2024
diaTribe Foundation Comments Re: Digital Health Advisory Committee — October 2024